July 24, 2013

Even though customers may only buy certain OTC categories a few times a year, for consumer healthcare brands, the opportunities to have a more meaningful relationship in the lives of their consumers has never been greater, Stefan Merlo, director of healthcare strategy, Novartis Consumer Health, told DSNtv in a special edition of DSN Executive Viewpoints.

June 24, 2015

Aurobindo Pharma Limited has announced that it has received final approval from the U.S. Food and Drug Administration for entacapone tablets USP, 200 mg, the generic equivalent to Comtan Tablets 200 mg.

June 12, 2015

The drug is a daily oral treatment for children 6 and up with chronic immune thrombocytopenia (ITP).

June 2, 2015

Perrigo's new OTC product portfolio acquired out of the GSK/Novartis joint venture are sold primarily throughout Europe and Brazil. 

May 7, 2015

Drug Store News on Sunday caught up with Brian McNamara, region head of Europe and the Americas of the recently christened GSK Consumer Healthcare, representing the joint venture between GlaxoSmithKline and Novartis to talk about what a consolidating OTC market means for the industry, and how GSK will be coming to market.

May 7, 2015

Kline reports OTC growth of 1.4% to more than $24 billion. 

April 24, 2015

Sandoz on Friday announced the launch of levoleucovorin injection ready-to-use single use vial, a generic version of Fusilev, which is marketed by Spectrum Pharmaceuticals. 

April 16, 2015

Sandoz on Thursday introduced a new generic MS therapy.

April 14, 2015

Ducere Pharma relaunched Cruex as a fungal nail revitalizing gel on Tuesday. 

April 14, 2015

Diplomat Pharmacy announced it will distribute Novartis' new medicine Jadenu, which is indicated to treat patients with chronic iron overload. 

March 31, 2015

Teva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension. 

 

March 13, 2015

Colgate announces changes to its board of directors, including the resignation of Joseph Jimenez, CEO of Novartis.

March 4, 2015

While the big four analgesic manufacturers — Bayer, Pfizer, McNeil and Novartis — command the lion’s share of retail ad support behind their mega analgesic brands, Prestige Brands and BedRock Brands are making headway promoting their niche pain relieving products.

February 27, 2015

GlaxoSmithKline expects to complete its Novartis transaction in the week commencing March 2.

February 26, 2015

The CDC’s Advisory Committee on Immunization Practices made a unanimous recommendation for use of meningococcal group B vaccines to vaccinate high-risk groups in the United States.

February 12, 2015

Sandoz on Thursday launched telmisartan tablets, the generic version of Micardis from Boehringer Ingelheim. The drug is used to treat hypertension, the company said.

 

February 3, 2015

Teva Pharmaceuticals on Tuesday announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in 10-mg dosage strength.

January 8, 2015

Camber Pharmaceuticals on Thursday announced the launch of valsartan tablets USP in 40-, 80-, 106- and 320-mg dosage strengths.

 

January 7, 2015

Lupin Pharmaceuticals on Tuesday launched its valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. The drug is the generic version Novartis's Diovan tablets.

January 7, 2015

Teva Pharmaceutical on Tuesday announced the Food and Drug Administration approved the launch of the company's valsartan tablets, the generic version of Diovan tablets from Novartis. 

 

January 6, 2015

Aurobindo Pharma on Tuesday announced that the company has received final approval from the U.S. Food & Drug Administration to manufacture and market Valsartan Tablets.

January 5, 2015

Mylan announced the introduction of valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. 

December 22, 2014

Mylan has announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of Novartis' Vivelle-DOT.

December 22, 2014

Sandoz has announced the U.S. market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot, which is marketed by Novartis Pharmaceuticals.